Nu Skin Enterprises (NUS)
Market Price (2/19/2026): $8.48 | Market Cap: $411.9 MilSector: Consumer Staples | Industry: Household Products
Nu Skin Enterprises (NUS)
Market Price (2/19/2026): $8.48Market Cap: $411.9 MilSector: Consumer StaplesIndustry: Household Products
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 42%, Dividend Yield is 2.9%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 37%, FCF Yield is 11% | Weak multi-year price returns2Y Excs Rtn is -88%, 3Y Excs Rtn is -146% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -14%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -13%, Rev Chg QQuarterly Revenue Change % is -17% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28% | Key risksNUS key risks include [1] persistent challenges in acquiring and retaining customers and affiliates, Show more. | |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, Personal Care & Beauty Innovations, and E-commerce & Digital Retail. Themes include Nutritional Supplements, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 42%, Dividend Yield is 2.9%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 37%, FCF Yield is 11% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, Personal Care & Beauty Innovations, and E-commerce & Digital Retail. Themes include Nutritional Supplements, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -88%, 3Y Excs Rtn is -146% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -14%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -13%, Rev Chg QQuarterly Revenue Change % is -17% |
| Key risksNUS key risks include [1] persistent challenges in acquiring and retaining customers and affiliates, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Nu Skin Enterprises (NUS) stock has lost about 20% since 10/31/2025 because of the following key factors:
1. Nu Skin Enterprises missed Fourth Quarter 2025 earnings and revenue estimates.The company reported Q4 2025 earnings per share (EPS) of $0.29, which fell short of analysts' consensus estimates of $0.30. Additionally, quarterly revenue came in at $370.32 million, missing the consensus estimate of $382.70 million. Revenue declined by 16.9% compared to the same period in the prior year.
2. The company issued a weak financial outlook for Q1 and full-year 2026.Nu Skin provided weaker-than-expected guidance for the first quarter of 2026, projecting revenue between $320.0 million and $340.0 million, and GAAP EPS of $0.10 to $0.20, both below analyst expectations. For the full fiscal year 2026, the company forecasted revenue between $1.35 billion and $1.50 billion and GAAP EPS of $0.80 to $1.20, also below consensus estimates. This guidance indicates anticipated continued revenue pressure in the near term.
Show more
1. Nu Skin Enterprises missed Fourth Quarter 2025 earnings and revenue estimates.The company reported Q4 2025 earnings per share (EPS) of $0.29, which fell short of analysts' consensus estimates of $0.30. Additionally, quarterly revenue came in at $370.32 million, missing the consensus estimate of $382.70 million. Revenue declined by 16.9% compared to the same period in the prior year.
2. The company issued a weak financial outlook for Q1 and full-year 2026.Nu Skin provided weaker-than-expected guidance for the first quarter of 2026, projecting revenue between $320.0 million and $340.0 million, and GAAP EPS of $0.10 to $0.20, both below analyst expectations. For the full fiscal year 2026, the company forecasted revenue between $1.35 billion and $1.50 billion and GAAP EPS of $0.80 to $1.20, also below consensus estimates. This guidance indicates anticipated continued revenue pressure in the near term.
Show more
Stock Movement Drivers
Fundamental Drivers
The -20.2% change in NUS stock from 10/31/2025 to 2/18/2026 was primarily driven by a -50.7% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 2182026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.66 | 8.50 | -20.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,626 | 1,485 | -8.7% |
| Net Income Margin (%) | 6.2% | 10.8% | 74.0% |
| P/E Multiple | 5.2 | 2.6 | -50.7% |
| Shares Outstanding (Mil) | 49 | 49 | 1.8% |
| Cumulative Contribution | -20.2% |
Market Drivers
10/31/2025 to 2/18/2026| Return | Correlation | |
|---|---|---|
| NUS | -20.2% | |
| Market (SPY) | 0.6% | 15.7% |
| Sector (XLP) | 15.4% | 4.1% |
Fundamental Drivers
The 2.5% change in NUS stock from 7/31/2025 to 2/18/2026 was primarily driven by a 13.2% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2182026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.29 | 8.50 | 2.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,679 | 1,485 | -11.6% |
| P/S Multiple | 0.2 | 0.3 | 13.2% |
| Shares Outstanding (Mil) | 50 | 49 | 2.5% |
| Cumulative Contribution | 2.5% |
Market Drivers
7/31/2025 to 2/18/2026| Return | Correlation | |
|---|---|---|
| NUS | 2.5% | |
| Market (SPY) | 8.9% | 25.7% |
| Sector (XLP) | 11.1% | 1.3% |
Fundamental Drivers
The 33.2% change in NUS stock from 1/31/2025 to 2/18/2026 was primarily driven by a 55.6% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2182026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.38 | 8.50 | 33.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,775 | 1,485 | -16.3% |
| P/S Multiple | 0.2 | 0.3 | 55.6% |
| Shares Outstanding (Mil) | 50 | 49 | 2.3% |
| Cumulative Contribution | 33.2% |
Market Drivers
1/31/2025 to 2/18/2026| Return | Correlation | |
|---|---|---|
| NUS | 33.2% | |
| Market (SPY) | 15.0% | 29.3% |
| Sector (XLP) | 13.6% | 16.1% |
Fundamental Drivers
The -77.9% change in NUS stock from 1/31/2023 to 2/18/2026 was primarily driven by a -94.9% change in the company's P/E Multiple.| (LTM values as of) | 1312023 | 2182026 | Change |
|---|---|---|---|
| Stock Price ($) | 38.41 | 8.50 | -77.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,377 | 1,485 | -37.5% |
| Net Income Margin (%) | 1.6% | 10.8% | 568.8% |
| P/E Multiple | 50.3 | 2.6 | -94.9% |
| Shares Outstanding (Mil) | 50 | 49 | 3.3% |
| Cumulative Contribution | -77.9% |
Market Drivers
1/31/2023 to 2/18/2026| Return | Correlation | |
|---|---|---|
| NUS | -77.9% | |
| Market (SPY) | 75.1% | 26.2% |
| Sector (XLP) | 28.4% | 22.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NUS Return | -4% | -14% | -51% | -64% | 43% | -10% | -81% |
| Peers Return | 19% | -48% | 7% | -45% | 19% | 12% | -52% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| NUS Win Rate | 42% | 50% | 25% | 33% | 42% | 50% | |
| Peers Win Rate | 67% | 27% | 53% | 38% | 42% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| NUS Max Drawdown | -26% | -36% | -60% | -68% | -20% | -13% | |
| Peers Max Drawdown | -8% | -55% | -28% | -52% | -34% | -3% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HLF, USNA, NATR, MED, EL. See NUS Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/18/2026 (YTD)
How Low Can It Go
| Event | NUS | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -73.8% | -25.4% |
| % Gain to Breakeven | 282.4% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -70.5% | -33.9% |
| % Gain to Breakeven | 239.5% | 51.3% |
| Time to Breakeven | 106 days | 148 days |
| 2018 Correction | ||
| % Loss | -55.9% | -19.8% |
| % Gain to Breakeven | 126.6% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -59.1% | -56.8% |
| % Gain to Breakeven | 144.7% | 131.3% |
| Time to Breakeven | 210 days | 1,480 days |
Compare to HLF, USNA, NATR, MED, EL
In The Past
Nu Skin Enterprises's stock fell -73.8% during the 2022 Inflation Shock from a high on 6/9/2021. A -73.8% loss requires a 282.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Nu Skin Enterprises (NUS)
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
AI Analysis | Feedback
1. Amway for premium anti-aging skincare and wellness.
2. Mary Kay, but focused on science-backed anti-aging and nutrition.
AI Analysis | Feedback
- Nutritional Supplements: A variety of dietary supplements under the Pharmanex brand, promoting wellness, vitality, and targeted nutritional support.
- Personal Care Products: Skincare, body care, hair care, and cosmetic items designed for beauty and anti-aging benefits.
- Beauty Devices: Innovative electronic devices that enhance skincare routines, often used in conjunction with specialized topical products.
AI Analysis | Feedback
Nu Skin Enterprises (NUS) is a global direct-selling company. It primarily sells its products (skincare, personal care, and nutritional supplements) directly to individuals, rather than to other companies.
Customer Categories for Nu Skin Enterprises (NUS):
- Brand Affiliates (Distributors): These are independent individuals who partner with Nu Skin to market and sell its products. They purchase products directly from Nu Skin (often at wholesale prices) not only for personal consumption but also to resell to others and to build and manage their own sales organizations. They are a fundamental part of Nu Skin's sales force and a major customer group as they acquire products from the company.
- End Consumers/Customers: These are individuals who purchase Nu Skin products for their own personal use. They acquire products either directly from Nu Skin's official websites and channels, or more commonly, through a Brand Affiliate. This category also includes "Members" or "Preferred Customers" who might sign up for discounts or recurring subscriptions without necessarily pursuing the business-building aspect of a Brand Affiliate.
AI Analysis | Feedback
nullAI Analysis | Feedback
Ryan Napierski, Chief Executive Officer & President Ryan Napierski is Nu Skin's chief executive officer and president, having served in this role since 2021. He joined the company in 1995 and has held numerous positions, including president of Nu Skin, president of global sales and operations, president of Nu Skin's North Asia region, and president of Nu Skin Japan. His earlier roles at Nu Skin include vice president of global business development, general manager for the United Kingdom, vice president of European business development, key account manager for United States executives, vice president of business development, and chief operating officer for the North Asia region. James D. Thomas, Executive Vice President, Chief Financial Officer James D. Thomas was appointed executive vice president and chief financial officer in July 2023. Prior to this, he served as interim chief financial officer since April 2023 and as chief accounting officer since 2019. Thomas joined Nu Skin in 2010 and has been instrumental in the company's mergers and acquisitions strategy. Before his time at Nu Skin, he worked as an assistant controller for another public, technology-enabled wellness company and in the assurance practice at PricewaterhouseCoopers LLP. Justin Keisel, Executive Vice President and President, Global Sales Justin Keisel serves as the executive vice president and president of global sales for Nu Skin. He brings over 27 years of experience within the beauty, wellness, and direct selling sectors. Keisel has expertise in overseeing customer-focused programs that drive rapid business growth in dynamic environments. He previously served as president of Nu Skin's Americas region, covering North America and South America. Steve Hatchett, Executive Vice President, Chief Product Officer Steve Hatchett was appointed executive vice president and chief product officer in 2021. He has been a member of Nu Skin's global management committee since 2018 and previously served as the senior vice president of global products. With over 30 years of experience, Hatchett brings expertise in global wellness and beauty innovation, design, scale-up, and manufacturing, including significant experience in the direct selling industry. Prior to Nu Skin, he worked at Forever Living Products and Mitsui International, and also founded Elevate Health Sciences, where he was CEO and a board member at Cornerstone Research and Development. Steven J. Lund, Executive Chairman of the Board Steven J. Lund is a co-founder of Nu Skin and serves as the executive chairman of the board. He has held several key roles within the company, including vice chairman of the board from 2006 to 2012, president and CEO from 1996 to 2003, and executive vice president of Nu Skin International. Lund has had a notable impact on his business, religious, and civic communities over several decades.AI Analysis | Feedback
The key risks to Nu Skin Enterprises (NUS) are primarily driven by global economic conditions and their impact on the company's direct-selling model.
- Macroeconomic Headwinds and Challenges in Customer and Affiliate Acquisition: Nu Skin has been significantly affected by persistent macroeconomic hurdles, including inflation, which pressure consumer spending and lead customers to seek lower-cost products. This environment has consistently impacted customer acquisition and retention globally, especially for Nu Skin's premium offerings. The company has reported declines in its customer base, paid affiliates, and sales leaders, indicating challenges in its core direct-selling business model.
- Volatile Foreign Currency Movements: Given Nu Skin's extensive international operations across nearly 50 markets, the company is highly exposed to the risk of volatile currency movements. Adverse foreign currency fluctuations have repeatedly resulted in negative impacts on reported revenues, significantly affecting financial performance.
- Declining Revenue and Profitability: Nu Skin has experienced a downward trend in revenue, with sales declining year-over-year in recent periods. This decline is coupled with shrinking operating margins and decreasing earnings per share (EPS), indicating difficulties in maintaining profitability amidst reduced demand and rising costs. This sustained decline in key financial metrics is a significant risk to the company's overall business quality and investor confidence.
AI Analysis | Feedback
There are two clear emerging threats for Nu Skin Enterprises:
- Shifting Consumer Sentiment and Skepticism Towards Direct Selling/Multi-Level Marketing (MLM) Models: Younger generations (Gen Z, Millennials) are increasingly skeptical of and publicly critical towards the MLM business model. This skepticism often stems from concerns about ethical recruitment practices, income transparency, high distributor churn rates, and the perceived pressure associated with direct selling interactions. This growing negative perception, amplified by social media and online discourse, poses an emerging threat to Nu Skin's ability to attract and retain new distributors and customers, which is fundamental to its growth and market expansion.
- Intensified Competition from Direct-to-Consumer (DTC) and E-commerce Beauty and Wellness Brands: The market is experiencing a proliferation of agile direct-to-consumer (DTC) and e-commerce brands that offer similar or highly specialized beauty, skincare, and nutritional products. These competitors often leverage sophisticated digital marketing, social media influencers, competitive pricing, and the convenience of direct online purchasing without an intermediary. This trend directly challenges Nu Skin's traditional reliance on its direct selling network, as consumers increasingly opt for the ease and perceived authenticity of purchasing directly from brands online, thereby eroding the unique value proposition of the direct selling model.
AI Analysis | Feedback
Nu Skin Enterprises (NYSE: NUS) operates in the global beauty and wellness markets, with its main products and services falling into categories such as beauty and personal care products (including skincare and beauty devices) and nutritional supplements. A significant focus for the company within these categories is anti-aging products and solutions. Here are the addressable market sizes for Nu Skin's main product categories:Global Beauty and Personal Care Products Market
The global beauty and personal care products market was valued at approximately USD 557.88 billion in 2024. This market is projected to grow to about USD 937.13 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7% from 2024 to 2030. Other estimates suggest the market could reach USD 818.42 billion in 2033 with a CAGR of 4.35% (2025-2033) or USD 802.6 billion by 2033 with a CAGR of 4.2% (2025-2033). The Asia-Pacific region holds the largest share of this market, accounting for 39.3% in 2023.Global Nutritional Supplements Market
The global nutritional supplements market was estimated at approximately USD 485.62 billion in 2024. This market is projected to reach about USD 704.28 billion by 2030, with a CAGR of 6.42% from 2025 to 2030. Other projections indicate the market could reach USD 816.57 billion by 2033, growing at a CAGR of 6.05% from 2025 to 2033. The Asia-Pacific region also holds the largest market share in nutritional supplements, at 39.63% in 2024.Global Anti-Aging Products Market
The global anti-aging products market, a significant segment for Nu Skin, was valued at around USD 65.24 billion in 2024. This market is predicted to grow to approximately USD 113.56 billion by 2034, with a CAGR of roughly 5.7% between 2025 and 2034. Other estimates place the market size at USD 52.44 billion in 2024, growing to USD 80.61 billion by 2030 with a CAGR of 7.7% (2025-2030). The anti-aging market in North America accounted for 30.4% of the global market revenue in 2024, while the Asia-Pacific region is forecast to expand at a 10.31% CAGR between 2025 and 2030.AI Analysis | Feedback
Nu Skin Enterprises (NUS) is expected to drive future revenue growth over the next 2-3 years through several key strategic initiatives:
- Launch and Expansion of the Prysm iO Platform: The introduction of the Prysm iO intelligent wellness platform is a significant catalyst for future growth. Following a limited preview for sales leaders in late Q4 2025, a broader consumer launch is anticipated in 2026. This AI-powered device is designed to measure skin carotenoid levels, provide personalized product recommendations, and is expected to boost the nutritional supplements division, potentially through subscription-based models.
- Expansion into the Indian Market: Nu Skin is strategically entering the Indian market, with pre-market opening activities beginning in Q4 2025 and a full-scale launch targeted for the second half of 2026. India is viewed as a substantial long-term opportunity due to its large and growing middle-class segment, and the company plans to enter with a localized product portfolio and a digital-first infrastructure.
- Growth in Emerging Markets: Nu Skin is focusing on accelerating growth in developing markets, particularly in Latin America and certain parts of Southeast Asia, which have shown strong sequential and double-digit year-over-year growth. The company plans to leverage a simplified and focused business model in these high-potential regions.
- New Product Launches and Innovation: Continuous innovation and the introduction of new products are crucial for Nu Skin's growth. Recent and ongoing launches, such as ageLOC WellSpa iO, RenuSpa iO, TRMe, and ageLOC Tru Face Peptide Retinol Complex, are expected to contribute to revenue by capturing greater market share in the beauty and wellness sectors.
- Strengthening the Rhyz Business Segment: The Rhyz segment, which includes manufacturing capabilities and affiliate marketing platforms like Mavely, is consistently highlighted for its strong performance and is expected to grow at a faster pace, contributing an anticipated 20% to 25% of overall revenue mix by 2025.
AI Analysis | Feedback
Share Repurchases
- Nu Skin repurchased $46.5 million of stock in Q2 2020, contributing to an approximately eight percent reduction in outstanding shares in the first half of 2020.
- The company did not repurchase any shares in Q3 2024 and Q4 2024.
- As of Q3 2025, Nu Skin repurchased $5.0 million in shares during the quarter and $10.0 million year-to-date, with $152.4 million remaining under its current share repurchase authorization. The authorized amount was $162.4 million as of Q4 2024.
Share Issuance
- Stock-based compensation, which typically involves share issuance to employees, was approximately $24.06 million in fiscal year 2020, $23.19 million in 2021, $12.37 million in 2022, $15.65 million in 2023, and $14.82 million in 2024.
Outbound Investments
- Nu Skin's strategic investment arm, Rhyz Inc., acquired the social commerce company Mavely in 2021. Nu Skin sold the Mavely platform for $250 million in January 2025, generating a five-times return on its 2021 investment.
- In 2023, the company acquired Dallas-based skincare company BeautyBio.
- Nu Skin Enterprises completed a merger/acquisition with LifeDNA as of May 3, 2023.
Capital Expenditures
- Nu Skin's capital expenditures were approximately $63.82 million in fiscal year 2020, $68.62 million in 2021, $59.06 million in 2022, $58.49 million in 2023, and $41.58 million in 2024.
- The primary focus of capital expenditures has been on strategic investments in technology and manufacturing, accelerating growth opportunities in Rhyz, and building out a digital-first affiliate opportunity platform.
- The company is also focusing investments on new market expansion, beginning with India anticipated in 2025, and advancing its Prysm iO intelligent wellness platform.
Latest Trefis Analyses
Trade Ideas
Select ideas related to NUS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01022026 | CALM | Cal-Maine Foods | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 7.3% | 7.3% | -7.7% |
| 01022026 | FIZZ | National Beverage | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 14.8% | 14.8% | 0.0% |
| 12192025 | LW | Lamb Weston | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 14.3% | 14.3% | -8.3% |
| 12052025 | CAG | Conagra Brands | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 18.2% | 18.2% | -5.7% |
| 12052025 | STZ | Constellation Brands | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 5.6% | 5.6% | -5.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 17.77 |
| Mkt Cap | 0.4 |
| Rev LTM | 1,199 |
| Op Inc LTM | 66 |
| FCF LTM | 39 |
| FCF 3Y Avg | 64 |
| CFO LTM | 59 |
| CFO 3Y Avg | 91 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -2.1% |
| Rev Chg 3Y Avg | -3.7% |
| Rev Chg Q | 4.2% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Mgn LTM | 5.6% |
| Op Mgn 3Y Avg | 6.3% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 5.8% |
| CFO/Rev 3Y Avg | 7.2% |
| FCF/Rev LTM | 3.7% |
| FCF/Rev 3Y Avg | 4.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.4 |
| P/S | 0.4 |
| P/EBIT | 5.3 |
| P/E | 12.9 |
| P/CFO | 11.7 |
| Total Yield | 4.1% |
| Dividend Yield | 0.1% |
| FCF Yield 3Y Avg | 9.8% |
| D/E | 0.2 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -6.2% |
| 3M Rtn | 16.0% |
| 6M Rtn | 4.2% |
| 12M Rtn | 38.7% |
| 3Y Rtn | -61.4% |
| 1M Excs Rtn | -5.3% |
| 3M Excs Rtn | 9.7% |
| 6M Excs Rtn | -4.7% |
| 12M Excs Rtn | 27.8% |
| 3Y Excs Rtn | -129.1% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Nu Skin | 1,753 | 2,072 | |||
| Manufacturing | 181 | 149 | |||
| Rhyz Other | 35 | 4 | |||
| Core Nu Skin adjustment | -1 | ||||
| Beauty | 1,443 | 1,492 | 1,423 | ||
| Other | 190 | 168 | 134 | ||
| Wellness | 1,063 | 923 | 863 | ||
| Total | 1,969 | 2,226 | 2,696 | 2,582 | 2,420 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Nu Skin | 376 | 425 | |||
| Manufacturing | 12 | 4 | |||
| Rhyz Other | -21 | -6 | |||
| Corporate and other | -320 | -311 | |||
| Total | 48 | 111 |
Price Behavior
Price Behavior
| Market Price | $8.50 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 11/22/1996 | |
| Distance from 52W High | -33.4% | |
| 50 Days | 200 Days | |
| DMA Price | $10.26 | $9.77 |
| DMA Trend | up | up |
| Distance from DMA | -17.2% | -13.0% |
| 3M | 1YR | |
| Volatility | 55.2% | 60.2% |
| Downside Capture | 12.29 | 54.41 |
| Upside Capture | -50.22 | 65.96 |
| Correlation (SPY) | 13.3% | 30.2% |
NUS Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.06 | 0.80 | 1.06 | 1.50 | 0.98 | 0.91 |
| Up Beta | -0.10 | -0.31 | 3.68 | 3.37 | 0.96 | 0.86 |
| Down Beta | 2.21 | 1.34 | 0.65 | 1.45 | 1.33 | 1.13 |
| Up Capture | 143% | 114% | 45% | 123% | 89% | 17% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 12 | 22 | 30 | 66 | 121 | 348 |
| Down Capture | -72% | 28% | 56% | 71% | 65% | 104% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 7 | 18 | 30 | 58 | 126 | 393 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NUS | |
|---|---|---|---|---|
| NUS | 15.5% | 60.2% | 0.47 | - |
| Sector ETF (XLP) | 11.4% | 14.1% | 0.53 | 19.1% |
| Equity (SPY) | 13.6% | 19.4% | 0.53 | 30.1% |
| Gold (GLD) | 73.5% | 25.5% | 2.13 | -10.8% |
| Commodities (DBC) | 7.9% | 17.0% | 0.28 | 3.9% |
| Real Estate (VNQ) | 7.1% | 16.7% | 0.24 | 23.4% |
| Bitcoin (BTCUSD) | -31.1% | 44.9% | -0.69 | 10.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NUS | |
|---|---|---|---|---|
| NUS | -30.6% | 47.3% | -0.60 | - |
| Sector ETF (XLP) | 8.6% | 13.1% | 0.44 | 27.3% |
| Equity (SPY) | 13.5% | 17.0% | 0.63 | 32.5% |
| Gold (GLD) | 21.7% | 17.1% | 1.04 | -0.8% |
| Commodities (DBC) | 10.8% | 19.0% | 0.45 | 3.6% |
| Real Estate (VNQ) | 4.9% | 18.8% | 0.17 | 30.9% |
| Bitcoin (BTCUSD) | 8.4% | 57.2% | 0.37 | 12.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NUS | |
|---|---|---|---|---|
| NUS | -9.8% | 49.1% | -0.03 | - |
| Sector ETF (XLP) | 8.6% | 14.6% | 0.45 | 20.0% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 31.2% |
| Gold (GLD) | 15.0% | 15.6% | 0.80 | -2.4% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 13.3% |
| Real Estate (VNQ) | 6.9% | 20.7% | 0.30 | 26.5% |
| Bitcoin (BTCUSD) | 68.0% | 66.7% | 1.07 | 11.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/12/2026 | -18.1% | ||
| 11/6/2025 | -15.8% | -9.7% | -7.4% |
| 8/7/2025 | 8.9% | 39.5% | 41.1% |
| 5/8/2025 | 11.0% | 21.3% | 31.5% |
| 2/13/2025 | 17.8% | 18.4% | 29.5% |
| 11/7/2024 | 1.6% | 11.5% | 21.7% |
| 8/8/2024 | -3.2% | -5.1% | -29.4% |
| 5/8/2024 | 2.9% | 9.4% | 7.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 11 | 12 |
| # Negative | 14 | 13 | 12 |
| Median Positive | 8.9% | 9.8% | 15.5% |
| Median Negative | -8.5% | -8.9% | -13.4% |
| Max Positive | 27.9% | 39.5% | 45.5% |
| Max Negative | -20.7% | -29.5% | -44.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/13/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/15/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/16/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hatchett, Steven Keith | Chief Product Officer | Direct | Buy | 11122025 | 9.61 | 5,500 | 52,855 | 1,610,300 | Form |
| 2 | Nathanson, Laura | Direct | Sell | 9042025 | 12.22 | 6,489 | 79,296 | 405,081 | Form | |
| 3 | Clark, Chayce David | EVP and General Counsel | Direct | Sell | 9042025 | 11.97 | 20,000 | 239,400 | 2,790,686 | Form |
| 4 | Campbell, Daniel W | Direct | Sell | 8292025 | 12.12 | 9,046 | 109,638 | 475,298 | Form | |
| 5 | Campbell, Daniel W | an irrevocable family trust | Sell | 8292025 | 12.10 | 23,391 | 283,031 | 645,838 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.